| Epithelial ovarian cancer S Lheureux, C Gourley, I Vergote, AM Oza The Lancet 393 (10177), 1240-1253, 2019 | 1330 | 2019 |
| Epithelial ovarian cancer: evolution of management in the era of precision medicine S Lheureux, M Braunstein, AM Oza CA: a cancer journal for clinicians 69 (4), 280-304, 2019 | 1073 | 2019 |
| Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab SV Bratman, SYC Yang, MAJ Iafolla, Z Liu, AR Hansen, PL Bedard, ... Nature Cancer 1 (9), 873-881, 2020 | 307 | 2020 |
| PARP inhibitors in the management of ovarian cancer: ASCO guideline WP Tew, C Lacchetti, A Ellis, K Maxian, S Banerjee, M Bookman, ... Obstetrical & Gynecological Survey 75 (12), 739-741, 2020 | 246 | 2020 |
| Survival with cemiplimab in recurrent cervical cancer KS Tewari, BJ Monk, I Vergote, A Miller, AC de Melo, HS Kim, YM Kim, ... New England Journal of Medicine 386 (6), 544-555, 2022 | 219 | 2022 |
| FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature N Aide, RJ Hicks, C Le Tourneau, S Lheureux, S Fanti, E Lopci European journal of nuclear medicine and molecular imaging 46, 238-250, 2019 | 217 | 2019 |
| Treatment strategies for endometrial cancer: current practice and perspective YC Lee, S Lheureux, AM Oza Current Opinion in Obstetrics and Gynecology 29 (1), 47-58, 2017 | 179 | 2017 |
| Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ... The Lancet 397 (10271), 281-292, 2021 | 146 | 2021 |
| Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus–related cervical carcinoma S Lheureux, MO Butler, B Clarke, MC Cristea, LP Martin, K Tonkin, ... JAMA oncology 4 (7), e173776-e173776, 2018 | 135 | 2018 |
| Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization S Lheureux, Z Lai, BA Dougherty, S Runswick, DR Hodgson, KM Timms, ... Clinical Cancer Research 23 (15), 4086-4094, 2017 | 133 | 2017 |
| Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis JL Ethier, DN Desautels, AJ Templeton, A Oza, E Amir, S Lheureux Gynecologic oncology 145 (3), 584-594, 2017 | 116 | 2017 |
| Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition S Lheureux, JP Bruce, JV Burnier, K Karakasis, PA Shaw, BA Clarke, ... Journal of clinical oncology 35 (11), 1240-1249, 2017 | 92 | 2017 |
| EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression S Lheureux, A Oaknin, S Garg, JP Bruce, A Madariaga, NC Dhani, ... Clinical Cancer Research 26 (16), 4206-4215, 2020 | 88 | 2020 |
| Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy N Vigneron, M Meryet-Figuière, A Guttin, JP Issartel, B Lambert, M Briand, ... Molecular oncology 10 (7), 981-992, 2016 | 86 | 2016 |
| Nanocarriers for the targeted treatment of ovarian cancers J Tomasina, S Lheureux, P Gauduchon, S Rault, A Malzert-Fréon Biomaterials 34 (4), 1073-1101, 2013 | 83 | 2013 |
| Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long-and short-term survivors SYC Yang, S Lheureux, K Karakasis, JV Burnier, JP Bruce, DL Clouthier, ... Genome medicine 10, 1-17, 2018 | 82 | 2018 |
| Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician S Lheureux, C Denoyelle, PS Ohashi, JS De Bono, FM Mottaghy European journal of nuclear medicine and molecular imaging 44, 41-54, 2017 | 76 | 2017 |
| Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach G Samimi, MQ Bernardini, LC Brody, CF Caga-Anan, IG Campbell, ... Journal of Clinical Oncology 35 (20), 2329-2337, 2017 | 76 | 2017 |
| F18-choline, a novel PET tracer for parathyroid adenoma? E Quak, S Lheureux, Y Reznik, S Bardet, N Aide The Journal of Clinical Endocrinology & Metabolism 98 (8), 3111-3112, 2013 | 74 | 2013 |
| Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations A Madariaga, S Lheureux, AM Oza Cancers 11 (3), 416, 2019 | 71 | 2019 |
